Responsum for CKD
{{user.displayName ? user.displayName : user.userName}}
{{ user.userType }}
Already a member?
Sign inBecome part of the foremost online community!
Sign Up NowOr, download the Responsum for CKD app on your phone
HCP Live and Bayer
A new phase 3 trial shows finerenone may slow kidney function decline in people with chronic kidney disease without diabetes. Learn what the FIND-CKD results mean.
A new clinical trial suggests that finerenone (Kerendia) may help slow the progression of chronic kidney disease (CKD) in people who do not have diabetes.*
The findings come from the phase 3 FIND-CKD trial, which studied more than 1,500 adults living with non-diabetic CKD. Early results showed that the medication helped slow the decline of kidney function compared with a placebo.
If confirmed through regulatory review, the results could expand treatment options for people with CKD caused by conditions other than diabetes.
Finerenone (brand name Kerendia) is a medication that blocks certain hormone signals in the body that can cause inflammation and scarring in the kidneys and heart.
The drug was first approved by the U.S. Food and Drug Administration (FDA) in 2021 for adults with CKD related to type 2 diabetes, after studies showed it could help reduce kidney disease progression and cardiovascular complications.
Researchers are now exploring whether the medication can also benefit people with other types of chronic kidney disease.
The FIND-CKD trial enrolled more than 1,500 adults with CKD who did not have diabetes.
Participants had kidney disease caused by a variety of conditions, including:
All participants were already taking standard kidney-protective medications known as RAS blockers, such as ACE inhibitors or ARBs.
Researchers randomly assigned participants to receive either:
Participants were followed for about 32 months to track changes in kidney function.
The study measured how quickly kidney function declined over time using a marker called estimated glomerular filtration rate (eGFR).
Researchers looked specifically at eGFR slope, which measures how fast kidney function decreases each year. A slower decline suggests that a treatment may help delay kidney disease progression.
Early results showed that people taking finerenone had a significantly slower decline in kidney function compared with those taking a placebo.
These findings suggest the medication may help slow CKD progression in patients without diabetes, although full results will be presented at an upcoming scientific meeting.
Finerenone has already been studied in several large clinical trials.
In the FIND-CKD study, researchers reported that the drug’s safety profile was consistent with previous studies.
As with other medications in the same class, dosing in the trial was adjusted based on kidney function and potassium levels to help reduce potential risks such as high potassium levels (hyperkalemia).
No new safety concerns were reported in the initial results.
Many CKD treatments studied in the past have focused on kidney disease caused by diabetes.
However, millions of people live with CKD that develops from other conditions such as high blood pressure or autoimmune diseases.
According to study co-chair Dr. Hiddo Heerspink, a professor of Clinical Trials and Personalized Medicine at the University Medical Center Groningen:
“Patients with chronic kidney disease have substantial risk for cardiovascular events and kidney failure, so new treatments are needed to help slow kidney disease progression and improve outcomes.”
The FIND-CKD results provide early evidence that finerenone may help a broader group of CKD patients.
Finerenone has been studied in several large trials across different heart and kidney conditions.
Earlier studies showed benefits for people with CKD and type 2 diabetes, while additional research has explored the medication’s role in heart failure and other kidney disease populations.
The FIND-CKD trial adds to this growing body of research by focusing specifically on CKD in patients without diabetes.
Based on the positive trial results, Bayer, the manufacturer of finerenone, plans to submit the data to the FDA to seek approval for use in patients with non-diabetic CKD.
If approved, this could significantly expand the number of people who may benefit from the medication.
However, finerenone is not yet approved for CKD without diabetes, and more detailed study results are expected soon.
While the results are promising, treatment decisions should always be made in consultation with your healthcare provider.
If you are living with CKD, your care team may already be discussing strategies to help slow disease progression, including:
As research continues, new treatments like finerenone may offer additional options for protecting kidney health.
The information provided by Responsum Health is for educational purposes only and does not replace professional medical advice. Always talk with your healthcare provider before making changes to your treatment or care. Responsum Health does not endorse specific treatments, providers, or products.
Source: {{articlecontent.article.sourceName}}
Receive daily updated expert-reviewed article summaries. Everything you need to know from discoveries, treatments, and living tips!
Already a Responsum member?
Available for Apple iOS and Android
We've sent a report to our community managers who will take the necessary steps. This member will be removed form your Community Chat and will no longer be able to message you.
Please contact us if you have any questions.
Add Comments
Cancel